PainQx Executive Summary 8/4/2015 Business Summary: PainQx, licensed from the NYU School of Medicine and in collaboration with Technische Universität Munich, is developing an accurate and objective method to measure pain in humans. Our patented technology delivers an accurate pain score to

clinical users in real time via cloud-based software, on a pay-per-use or subscription basis. PainQx is accurate, objective and consistent in contrast to the current standard of care, the subjective, patient self-report 0 -10 scale, e.g. Visual Analog Scale: (VAS) Current Position: PainQx is an early stage, clinical, pre- revenue company. Customer Problem/ Unmet Need: Pain Assessment relies entirely on subjective patient self-report. Accurate pain measurement is critical for proper medical diagnosis and appropriate treatment, yet practitioners and researchers do not have a way to objectively measure pain. Product/Service: PainQx is a SaaS healthcare model which analyzes, decodes and quantifies brain electrical activity through patented algorithms to produce an accurate pain score in real time. Value Proposition: The ability to describe and accurately measure pain is essential to understand patient pain mechanisms, provide effective treatments, and develop new treatments. Key Examples:

Drug Development Clinical Trials: Early Revenue Stream prior to FDA 510K approval

Clinical Assessment Tool using brain electrical activity as a scaled pain biomarker Improve data quality and reduce number of subjects needed Reduce Costs & Risks involved in expensive Pain Clinical Trials (Avg. cost = $105M)

Payors Value:

Cost Reduction: Payor’s estimate saving $8,400/ yr. per chronic pain patient Quality Measures & Monitoring Capability

Provider Value:

Measure pain in patient populations that cannot accurately articulate or express pain (e.g. unconscious/ general anesthesia patients, pediatric, elderly)

Solve Under-treatment / Over-treatment dilemma, especially over use of opioid narcotics and analgesic drugs

Total Available Market: More than 116 million people suffer from chronic pain in the U.S. every year representing over a $2 billion dollar market potential. Customers: CROs and Pain Pharma Franchise Clinical Trials , Nursing Homes/ Assisted Living Centers, Chronic Pain Centers, and Hospitals (ER, Inpatient, Outpatient) Sales and Marketing Strategy: PainQx will develop an untapped objective pain assessment market in human healthcare. We are developing alliances with CROs/ Pharma companies, Hospital / Pain Clinic Healthcare networks, Insurance Payors, EEG manufacturers, and Medical Device Channel sales force partners to generate early revenue, secure validation, advocacy, reimbursement and usage. Revenue Model: Early revenue realized in first year for PainQx usage in Research Clinical Trials prior to FDA approval. Post FDA approval, revenues will be earned by selling PainQx on either a pay-per-use or subscription basis to CROs, Pain Clinics, Nursing Homes and Hospitals. Payor reimbursement support will be demonstrated not only through payor pilot cost saving programs, but also by PainQx’s ability to provide a metric for patient outcomes. PainQx fits the emerging ACO driven, Value Based healthcare ecosystem where physicians, hospitals/ medical groups are rewarded for better health outcomes/ performance measures. Intellectual Property:

Exclusive, worldwide, sub-licensable, long term patent rights from NYU for patent suite

Patents Issued in Japan and China; Patent applications in U.S., Canada, Europe Competitors: fMRI, PET & MEG scans could be used to gather brain signals data that could potentially be used to measure pain. All have limitations and disadvantages (size, high capital / operational costs, non-portable, patient invasiveness) which make them incompatible and unviable at the point of care. In addition, any neuro-imaging input would need to utilize PainQx’s proprietary algorithms in order to produce a pain score. No commercial competitors exist at this time. Competitive Advantage:

Use of Funds: We seek to raise $500,000 from early investors to develop PainQx to its first milestone/ inflection point while earning revenue in the first year of development. $9 million will be needed to develop the PainQx system. Projections include expenses for the development of the algorithm, validation trials and registration support.

Accurate, objective & reliable pain score Proprietary System difficult to replicate

Scalable, inexpensive, established technology. Proprietary Pain Database

Financial Info Amount

Capital Raised $1.3M

Monthly Cash

Flow to First

Milestone

$50,000 upon

seed funding

Capital Seeking

Short term goal:

Midterm goal:

$ 500K

Angel Round

$ 4.5M Series A

Sales Forecast:

Year 1:

$ 6M

Year 3:

$ 36M

Year 5:

$164M

Preferred

Funding

Equity

Company Info:

URL: www.painqx.com

Contact: fminella@painqx.com

Phone: 610.348.9153

Industry: Healthcare

Employees: 5

Founded: 2015

Founder/ CEO:

Mr. Frank A. Minella

Serial Entrepreneur

Business Management Consultant:

Accenture – Pharma Group

24 years’ experience in Military

Command Leadership &

Commercial Business Management

U.S. Army Aviator / Officer

Chief Financial Officer:

Mr. Alexander Ruckdaeschel

Serial Entrepreneur with 20 years’

Business Financial Management

experience worldwide

Partner of Alpha Plus Advisors,

LLC. Co-Founder and Principal of

Blue Rock-AG, Investment

Advisor, Nanostart AG

German Military Special Forces,

United Nations Advisor/

Peacekeeper

Chief Science Advisor & Inventor

Leslie Prichep, PhD.

Acting Director, Brain Research

Laboratories, NYU School of

Medicine

Serial entrepreneur, whose patents

have been successfully

commercialized 3 times

Professor of Psychiatry, NYU

Medical School & world leader,

expert in QEEG

Manages one of the world’s largest

QEEG databases on chronic pain